skip to Main Content

Closeup of molecules Breaking News: Orphan status granted to PVSRIPO for advanced melanoma LEARN MORE Closeup of molecules Watch our latest video about PVSRIPO's mechanism of action VIEW HERE Closeup of molecules Phase 1 Melanoma Trial Data Presented LEARN MORE IND Now Open for LUMINOS-102 Trial in Melanoma LEARN MORE First Patient Dosed in LUMINOS-101 LEARN MORE

Closeup of molecules Breaking News: Orphan status granted to PVSRIPO for advanced melanoma LEARN MORE Closeup of molecules Watch our latest video about PVSRIPO's mechanism of action VIEW HERE Closeup of molecules Phase 1 Melanoma Trial Data Presented LEARN MORE IND Now Open for LUMINOS-102 Trial in Melanoma LEARN MORE First Patient Dosed in LUMINOS-101 LEARN MORE

Revolutionizing cancer care.

PVSRIPO is an investigational intratumoral immunotherapy based on the Sabin type-1 polio vaccine. Learn more about how this novel approach to viral immunotherapy could provide a safer, more effective approach to immune activation against cancer.

Reshaping the Standard of Care for the Treatment of Cancer

Istari Oncology is a clinical-stage biotechnology company focused on developing and commercializing groundbreaking immuno-oncology therapies with the potential to improve the standard of care for a wide range of solid tumors, including glioblastoma and melanoma.

TECHNOLOGIES IN CLINICAL DEVELOPMENT

Polio Virus Sabin-Rhinovirus Poliovirus (PVSRIPO)

Antibody Toxin Conjugates (ATCs)

Orange circle with white brain icon inside

OUR SCIENCE

Find out more about our breakthrough PVSRIPO platform

Green circle with white arrows inside

PIPELINE

For more on how our technologies are advancing

Fuchsia circle with white newspaper icon inside

NEWS

Access the latest updates and research

Back To Top
×Close search
Search